AI assistant
Teva Pharmaceutical Industries Ltd. — Director's Dealing 2021
Mar 8, 2021
7082_dirs_2021-03-08_92ac56ac-e1c7-479a-bbab-9347869b1e56.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK: 0000818686
Period of Report: 2021-03-04
Reporting Person: Sabag Mark (See "Remarks" below)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-04 | Ordinary Shares | M | 15920 | — | Acquired | 147842 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-03-04 | Restricted Share Units | $ | M | 15920 | Disposed | Ordinary Shares (15920) | Direct | |
| 2021-03-05 | Restricted Share Units | $ | A | 95057 | Acquired | Ordinary Shares (95057) | Direct |
Footnotes
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3: Restricted share units were granted on March 4, 2019, with 15,920 vesting on each of March 4, 2021 and March 4, 2022 and 15,921 vesting on March 4, 2023.
F4: Restricted share units were granted on March 5, 2021, with 23,764 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 23,765 vesting on March 5, 2025.